SAN FRANCISCO (MarketWatch) -- Acusphere Inc. ACUS, shares tumbled 27% to $3.02 in Tuesday morning trade. The Watertown, Mass.-based pharmaceutical company said Imagify met the primary endpoints for ...

Acusphere, Inc. (ACUSD.PK) today announced that it has submitted the Marketing Authorisation Application (MAA) for its lead product candidate, Imagify™ (Perflubutane Polymer Microspheres) lyophilisate ...

NEW YORK, May 1 (Reuters) - Acusphere Inc.'s experimental imaging agent for measuring blood flow in the heart met or exceeded two of its three main goals in a clinical trial that will be used to seek ...

LEXINGTON, Mass.--(BUSINESS WIRE)-- Acusphere, Inc. (ACUSD.PK) today announced that it has submitted the Marketing Authorisation Application (MAA) for its lead product candidate, Imagify™ ...

SILVER SPRING, Md., Dec 10 (Reuters) - A U.S. Food and Drug Administration advisory panel rejected Acusphere Inc's imaging contrast agent on Wednesday, saying possible risks outweighed its potential ...

WATERTOWN, Mass., Dec 10, 2008 (BUSINESS WIRE) -- Acusphere, Inc. today announced that NASDAQ has halted trading in the Company's common stock today. The Cardio Renal Advisory Committee to the U.S.

Acusphere Inc. announced the submission of a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for approval to market its lead product candidate, Imagify™ (Perflubutane Polymer ...